Literature DB >> 27388327

Drug Resistance Reversal Potential of Isoliquiritigenin and Liquiritigenin Isolated from Glycyrrhiza glabra Against Methicillin-Resistant Staphylococcus aureus (MRSA).

Rashmi Gaur1, Vivek Kumar Gupta2, Pooja Singh1, Anirban Pal2, Mahendra Padurang Darokar2, Rajendra Singh Bhakuni3.   

Abstract

Isoliquiritigenin (ISL) and liquiritigenin (LTG) are structurally related flavonoids found in a variety of plants. Discovery of novel antimicrobial combinations for combating methicillin-resistant Staphylococcus aureus (MRSA) infections is of vital importance in the post-antibiotic era. The present study was taken to explore the in vitro and in vivo combination effect of LTG and ISL with β-lactam antibiotics (penicillin, ampicillin and oxacillin) against mec A-containing strains of MRSA. Minimum inhibitory concentration (MIC) of both LTG and ISL exhibited significant anti-MRSA activity (50-100 µg/mL) against clinical isolates of MRSA. The result of in vitro combination study showed that ISL significantly reduced MIC of β-lactam antibiotics up to 16-folds [∑ fractional inhibitory concentration (FIC) 0.312-0.5], while LTG reduced up to 8-folds (∑FIC 0.372-0.5). Time kill kinetics at graded MIC combinations (ISL/LTG + β-lactam) indicated 3.27-9.79-fold and 2.59-3.48-fold reduction in the growth of clinical isolates of S. aureus respectively. In S. aureus-infected Swiss albino mice model, combination of ISL with oxacillin significantly (p < 0.05, p < 0.01, p < 0.001) lowered the systemic microbial burden in blood, liver, kidney, lung and spleen tissues in comparison with ISL, oxacillin alone as well as untreated control. Considering its synergistic antibacterial effect, we suggest both ISL and LTG as promising compounds for the development of novel antistaphylococcal combinations.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Glycyrrhiza glabra; antibacterial activity; isoliquiritigenin; liquiritigenin; synergism

Mesh:

Substances:

Year:  2016        PMID: 27388327     DOI: 10.1002/ptr.5677

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  6 in total

1.  Isoliquiritigenin decreases the incidence of colitis-associated colorectal cancer by modulating the intestinal microbiota.

Authors:  Minna Wu; Yaqi Wu; Baoguo Deng; Jinsong Li; Haiying Cao; Yan Qu; Xinlai Qian; Genshen Zhong
Journal:  Oncotarget       Date:  2016-12-20

2.  In vitro and in vivo activity of d-serine in combination with β-lactam antibiotics against methicillin-resistant Staphylococcus aureus.

Authors:  Qing Wang; Yuemeng Lv; Jing Pang; Xue Li; Xi Lu; Xiukun Wang; Xinxin Hu; Tongying Nie; Xinyi Yang; Yan Q Xiong; Jiandong Jiang; Congran Li; Xuefu You
Journal:  Acta Pharm Sin B       Date:  2019-01-31       Impact factor: 11.413

Review 3.  Pharmacological Effects and Underlying Mechanisms of Licorice-Derived Flavonoids.

Authors:  Yufan Wu; Zhuxian Wang; Qunqun Du; Zhaoming Zhu; Tingting Chen; Yaqi Xue; Yuan Wang; Quanfu Zeng; Chunyan Shen; Cuiping Jiang; Li Liu; Hongxia Zhu; Qiang Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-17       Impact factor: 2.629

Review 4.  Traditional Uses, Pharmacological Effects, and Molecular Mechanisms of Licorice in Potential Therapy of COVID-19.

Authors:  Qian-Hui Zhang; Hao-Zhou Huang; Min Qiu; Zhen-Feng Wu; Zhan-Chang Xin; Xin-Fu Cai; Qiang Shang; Jun-Zhi Lin; Ding-Kun Zhang; Li Han
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

5.  Comprehensive multivariate correlations between climatic effect, metabolite-profile, antioxidant capacity and antibacterial activity of Brazilian red propolis metabolites during seasonal study.

Authors:  Ticiano Gomes do Nascimento; Rodolfo Elleson Dos Santos Arruda; Erika Tayse da Cruz Almeida; José Marcos Dos Santos Oliveira; Irinaldo Diniz Basílio-Júnior; Isabel Cristina Celerino de Moraes Porto; Adilson Rodrigues Sabino; Josealdo Tonholo; Alexander Gray; RuAngelie Edrada Ebel; Carol Clements; Tong Zhang; David George Watson
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

6.  In vitro activity and In vivo efficacy of Isoliquiritigenin against Staphylococcus xylosus ATCC 700404 by IGPD target.

Authors:  Qianwei Qu; Jinpeng Wang; Wenqiang Cui; Yonghui Zhou; Xiaoxu Xing; Ruixiang Che; Xin Liu; Xueying Chen; God'spower Bello-Onaghise; Chunliu Dong; Zhengze Li; Xiubo Li; Yanhua Li
Journal:  PLoS One       Date:  2019-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.